SanBio Co Ltd (JP:4592)
:4592
4592 Stock Chart & Stats
¥2230.00
¥19.00(2.53%)
At close: 4:00 PM EST
¥2230.00
¥19.00(2.53%)
Day’s Range― - ―
52-Week Range¥1,388.00 - ¥3,990.00
Previous CloseN/A
Volume765.40K
Average Volume (3M)2.08M
Market Cap
¥143.27B
Enterprise Value¥127.78B
Total Cash (Recent Filing)¥2.74B
Total Debt (Recent Filing)¥1.36B
Price to Earnings (P/E)―
Beta1.18
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding78,033,330
10 Day Avg. Volume2,869,570
30 Day Avg. Volume2,080,090
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,866.67Price Target Upside-16.29% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet ImprovementRecent equity growth and asset expansion have improved solvency on paper, reducing immediate liquidity pressure and extending runway versus peers. Manageable debt-to-equity in 2023–2025 (~0.21–0.24) implies limited leverage under normal conditions, supporting financing flexibility.
Proprietary CNS Cell-therapy FocusA concentrated cell-therapy platform targeting CNS disorders creates a durable competitive position: technical specialization raises entry barriers, aligns R&D efforts, and enhances potential for valuable IP or strategic partnerships if clinical programs advance, supporting long-term upside.
Improving Cash Burn TrendYear-over-year reduction from peak cash burn suggests management may be moderating spend or improving operational efficiency. If this trend continues, it can lengthen the financing runway, reduce near-term dilution risk, and improve the company's ability to execute programs without constant refinancing.
Bears Say
No Commercial RevenueThe company remains pre-revenue with persistent large net losses and deeply negative EBIT, indicating it has not established a commercial earnings base. Long-term value is therefore contingent on successful clinical outcomes or licensing, which increases binary execution risk for investors and creditors.
Persistent Negative Cash FlowSustained negative operating and free cash flow demonstrates ongoing cash burn and structural funding needs. This compels repeated access to external capital or partnerships, raising dilution and refinancing risk and potentially forcing program delays or reprioritization if financing conditions tighten.
Financing Volatility RiskA prior sharp increase in leverage shows the capital structure can deteriorate rapidly under funding stress. That history signals the company may face abrupt refinancing or covenant pressure in adverse scenarios, limiting strategic optionality and increasing downside risk during clinical or market setbacks.
SanBio Co News
4592 FAQ
What was SanBio Co Ltd’s price range in the past 12 months?
SanBio Co Ltd lowest stock price was ¥1388.00 and its highest was ¥3990.00 in the past 12 months.
What is SanBio Co Ltd’s market cap?
SanBio Co Ltd’s market cap is ¥143.27B.
When is SanBio Co Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were SanBio Co Ltd’s earnings last quarter?
Currently, no data Available
Is SanBio Co Ltd overvalued?
According to Wall Street analysts SanBio Co Ltd’s price is currently Overvalued.
Does SanBio Co Ltd pay dividends?
SanBio Co Ltd does not currently pay dividends.
What is SanBio Co Ltd’s EPS estimate?
SanBio Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SanBio Co Ltd have?
SanBio Co Ltd has 78,033,330 shares outstanding.
What happened to SanBio Co Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SanBio Co Ltd?
Currently, no hedge funds are holding shares in JP:4592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SanBio Co Ltd
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
4592 Company Deck
4592 Earnings Call
Q4 2026
0:00 / 0:00
4592 Stock 12 Month Forecast
Average Price Target
¥1,866.67
▼(-16.29% Downside)
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---